PRO 140 for Human Immunodeficiency Virus Infection



Status:Recruiting
Conditions:HIV / AIDS, HIV / AIDS, HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:2/8/2015
Start Date:September 2014
End Date:September 2016
Contact:Meghan Metz, MS CCRP
Email:Meghan.Metz@DrexelMed.edu
Phone:267-507-6769

Use our guide to learn which trials are right for you!

PRO 140 2103: A Phase 2a, Randomized Study of PRO 140 by Subcutaneous Injection in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection

PRO 140 2103 is a multicenter, randomized parallel group study, conducted in male and female
adult subjects infected with CCR5-tropic HIV-1.

Protocol PRO 140 2103 is a multicenter, randomized parallel group study, conducted in
approximately 40 male and female adult subjects (n=10/treatment group) infected with
CCR5-tropic HIV-1. Subjects will be randomized into one of four treatment groups. Blood
samples for drug concentrations, PD variables, and efficacy variables will be obtained over
a 59-day period following initiation of dosing. Safety will be monitored throughout the
course of the study.

Inclusion Criteria:

1. Males and females, age ≥18 years

2. Has not taken any antiretroviral therapy (ART) within 12 weeks of the early screening
visit

3. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL

4. CD4+ lymphocyte cell count ≥500 cells/mm3 and no documented count less than or equal
to 250 cells/mm3

5. Exclusive CCR5-tropic virus as determined by as determined by the Enhanced
Sensitivity Trofile™ HIV Tropism Assay

6. Clinically normal resting 12-lead ECG at screening visit

7. Women of reproductive potential must have a negative serum pregnancy test at Late
Screening Visit. Within hours prior to receiving the first dose of study drug, women
of reproductive potential must have a negative urine pregnancy test. Male and female
subjects must agree not to participate in a conception process and agree to use one
barrier method of contraception plus one other highly reliable contraceptive method
from the early screening visit through three weeks after the last administered
subcutaneous dose of PRO 140.

Exclusion Criteria:

1. CXCR4-tropic virus, dual/mixed tropic (R5X4) virus as determined by the Enhanced
Sensitivity Trofile™ HIV Tropism Assay

2. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant
during the study

3. Diagnosis of acute viral hepatitis (defined as any active infection with hepatitis A
or a new diagnosis of hepatitis B or C within 24 weeks of dosing)

4. Chronic hepatitis

5. Prior use of any entry, attachment, CCR5 coreceptor, or fusion inhibitor, including
PRO 140, experimental or approved

6. Any immunization or vaccination (including influenza vaccine) within 30 days prior to
administration of study drug.
We found this trial at
7
sites
?
mi
from
Houston, TX
Click here to add this to my saved trials
601 Elmwood Avenue
Rochester, New York 14642
(585) 275-2100
Univ of Rochester Medical Center One of the nation's top academic medical centers, the University...
?
mi
from
Rochester, NY
Click here to add this to my saved trials
1 Brookings Drive
St. Louis, Missouri 63110
 (314) 935-5000
Washington University Washington University creates an environment to encourage and support an ethos of wide-ranging...
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
2900 W Queen Ln
Philadelphia, Pennsylvania 19129
(215) 991-8100
Drexel University College of Medicine Drexel University College of Medicine represents the consolidation of two...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Stanford, CA
Click here to add this to my saved trials